Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort

Blood Cancer Journal, Published online: 09 August 2023; doi:10.1038/s41408-023-00890-yIbrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort

Source: Blood Cancer Journal - August 9, 2023 Category: Hematology Authors: Yi Miao Yeqin Sha Yi Xia Shuchao Qin Rui Jiang Luomengjia Dai Hui Shen Tonglu Qiu Wei Wu Jingyan Qiu Yilian Yang Chongyang Ding Yujie Wu Lei Fan Wei Xu Jianyong Li Huayuan Zhu Source Type: research